Analyst Expectations for Outlook Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Outlook Therapeutics (NASDAQ:OTLK) has received various analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, and 2 indifferent. The company has an average 12-month price target of $4.5, with a high of $10.00 and a low of $1.00. The current average price target is unchanged from the previous one.
August 31, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Outlook Therapeutics has received mixed analyst ratings, which could lead to uncertainty in the market. The unchanged average price target suggests a stable outlook.
The mixed analyst ratings indicate differing opinions about the company's future performance. This could lead to uncertainty among investors, potentially affecting the stock's price. However, the unchanged average price target suggests that the overall outlook for the company remains stable.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100